Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00134264 · ClinicalTrials.gov registry record · Phase 3
A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 15,067
- Enrollment target
NCT00134264: Clinical Trial Phase 3 study, sponsored by Pfizer.
NCT00134264 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 15,067 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1854% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00134264, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 15,067 participants
- Enrollment target
Study Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To demonstrate if torcetrapib/atorvastatin can reduce the risk for major cardiovascular disease events, when compared to atorvastatin alone, in patients with coronary heart disease or risk equivalents
Interventions
- DRUG atorvastatin
- DRUG torcetrapib/atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,067 participants |
| Start Date | 2004-07 |
| Est. Completion | 2007-06 |
| Phase | Phase 3 |
Why NCT00134264 stopped before completion
NCT00134264 is an interventional study that assigns participants to a tested intervention. Its 15,067 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1854% higher).
The record links to 0 conditions, and to 2 interventions - of which atorvastatin is the first listed.
NCT00134264 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00134264 about?
NCT00134264 is a clinical study titled "A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease". The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To demonstrate if torcetrapib/atorvastatin can reduce the risk for major cardiovascular disease events, when compared to atorvastatin alone, in patients with coronary heart disease or risk equivalents
What is the current status of trial NCT00134264?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 15,067 participants. The study started on 2004-07. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00134264?
The interventions under investigation include: atorvastatin (DRUG), torcetrapib/atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00134264?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00134264's enrollment target sits among peer trials
15,067 14th of 2000 higher than 1,987 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07000357 · 15,100 participants · Phase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- NCT00857922 · 15,000 participants
Neurosciences Research Repository
- NCT01137643 · 15,000 participants
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- NCT01550575 · 15,000 participants
Patient Retrospective Outcomes (PRO)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia